SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458506070235v1
13/3/348    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Feuillet, L.
Right arrow Articles by Attarian, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feuillet, L.
Right arrow Articles by Attarian, S.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Multiple Sclerosis
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Prospective clinical and electrophysiological follow-up on a multiple sclerosis population treated with interferon beta-1 a

a pilot study

L. Feuillet

Department of Neurology, Faculté de Médecine de Marseille, Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de La Timone, Marseille, France,feuillet{at}mail.ap-hm.fr

J. Pelletier

Department of Neurology, Faculté de Médecine de Marseille, Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de La Timone, Marseille, France

L. Suchet

Department of Neurology, Faculté de Médecine de Marseille, Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de La Timone, Marseille, France

A. Rico

Department of Neurology, Faculté de Médecine de Marseille, Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de La Timone, Marseille, France

A. Ali Cherif

Department of Neurology, Faculté de Médecine de Marseille, Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de La Timone, Marseille, France

J. Pouget

Department of Neurology and Neuromuscular Diseases, Faculté de Médecine de Marseille, Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de La Timone, Marseille, France

S. Attarian

Department of Neurology and Neuromuscular Diseases, Faculté de Médecine de Marseille, Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de La Timone, Marseille, France

Objective To analyse transcranial magnetic stimulation (TMS) variables in a prospective six-month follow-up pilot study on patients suffering from relapsing-remitting multiple sclerosis (RRMS), satisfying inclusion criteria for interferon (IFN) beta-1a treatment.

Background So far, no predictive factors are available as to the course of RRMS treated with IFN beta-1 a.

Design/methods Fifteen RRMS patients were studied before (month 0 (M0)) and after IFN beta-1a onset (M3, M6). The parameters analysed were motor functional score (mFS), Expanded Disability Status Scale (EDSS), and TMS variables - central motor conduction time (CMCT) and amplitude ratio (AR).

Results Four of the six patients with no motor signs at inclusion, subsequently showed signs of pyramidal dysfunction. All had abnormal M0_TMS variables. The number of M0_TMS abnormalities per patient was greatest in the group that showed mFS worsening, and was significantly correlated with M6_EDSS. The M0_CMCT was significantly correlated with M6_EDSS. During follow-up, the number of patients with abnormal TMS variables decreased from 12/15 to 4/15, and the total number of abnormalities decreased from 33.3 to 16.7%.

Conclusions TMS variables might be predictive of disease progression. The improvement observed here in the TMS variables may reflect an improvement in MS patients undergoing IFN beta treatment. Multiple Sclerosis 2007; 13: 348-356. http://msj.sagepub.com

Key Words: evoked potentials • humans • interferon beta • multiple sclerosis • neurophysiology • transcranial magnetic stimulation

This version was published on April 1, 2007

Multiple Sclerosis, Vol. 13, No. 3, 348-356 (2007)
DOI: 10.1177/1352458506070235


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Mult SclerHome page
A Rico, B Audoin, J Franques, A Eusebio, F Reuter, I Malikova, A Ali Cherif, J Pouget, J Pelletier, and S Attarian
Motor evoked potentials in clinically isolated syndrome suggestive of multiple sclerosis
Multiple Sclerosis, March 1, 2009; 15(3): 355 - 362.
[Abstract] [PDF]



Advertisement